Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Century Therapeutics Q3 2026 Results: Net Loss of $23.5M, Loss Narrows

Century Therapeutics reported a total asset increase to $262.6 million as of September 30, 2026, driven by a significant increase in common stock issuance and long-term investments. The company's accumulated deficit grew to $871.6 million, reflecting ongoing development costs for its iPSC-derived immune cell therapies.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-23.5-34.4
EPS (diluted, $ a share)$-0.11$-0.40

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: IPSC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Century Therapeutics, Inc.: key numbers

Share price
$1.37Close, Nov 17
Market cap
$249M
Shares outstanding
181.6MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Century Therapeutics, Inc.

All →
7:17 AM ET 8-K
Financial Results

Century Therapeutics Financial Results

Century Therapeutics reported third quarter 2026 financial results and provided updates on its iPSC-derived cell therapy pipeline. The company remains on track for an IND submission for CNTY-813 in Q4 2026 and expects its CD19-targeted CAR-iT cell therapy, CNTY-308, to enter the clinic by the end of 2026.

“We remain focused on disciplined execution as we rapidly advance our two potentially transformational programs, including CNTY-813, which has the potential to be a functional cure for type 1 diabetes, toward the clinic over the coming months.”

Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics

“With general alignment reached with the FDA for both programs, we remain on track this year for clinical entry of CNTY-308 and IND submission of CNTY-813, positioning us for an important transition to clinical execution in 2027.”

Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics
8:19 AM ET 8-K
Clinical Trial Data

Century Therapeutics Clinical Trial Data

Century Therapeutics presented updated nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at the EASD 2026 meeting. The data demonstrated sustained glycemic control in diabetic mouse models for over eleven months and confirmed manufacturing consistency across five clinical-scale batches. The company remains on track to submit an IND for CNTY-813 in Q4 2026, with initial clinical data expected in the second half of 2027.

Counterparty
European Association for the Study of Diabetes (EASD)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.